Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Current Deferred Revenue (2016 - 2024)

Seres Therapeutics (MCRB) has disclosed Current Deferred Revenue for 9 consecutive years, with $7.9 million as the latest value for Q2 2024.

  • Quarterly Current Deferred Revenue rose 876.82% to $7.9 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $7.9 million through Jun 2024, up 876.82% year-over-year, with the annual reading at $7.7 million for FY2023, 81.5% up from the prior year.
  • Current Deferred Revenue hit $7.9 million in Q2 2024 for Seres Therapeutics, down from $8.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $22.6 million in Q4 2020 to a low of $364000.0 in Q3 2023.
  • Historically, Current Deferred Revenue has averaged $10.9 million across 5 years, with a median of $8.5 million in 2020.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 92.69% in 2023 and later soared 876.82% in 2024.
  • Year by year, Current Deferred Revenue stood at $22.6 million in 2020, then fell by 25.59% to $16.8 million in 2021, then crashed by 74.68% to $4.3 million in 2022, then soared by 81.5% to $7.7 million in 2023, then rose by 2.48% to $7.9 million in 2024.
  • Business Quant data shows Current Deferred Revenue for MCRB at $7.9 million in Q2 2024, $8.1 million in Q1 2024, and $7.7 million in Q4 2023.